In The News
‘Considerable disquiet’: Pelvic mesh group members can challenge $405M settlements
Judge rejects sacked Super Retail Group execs’ settlement claims
$56M settlement approved in Monash IVF class action
Kids clothing retailer hit with $5M penalty for worker exploitation
Third person sentenced over $180M Courtenay House Ponzi scheme
Lawyerly holiday publishing schedule
Johnson & Johnson hit with class action over cold and flu medications
ASIC, Noumi win appeal in privilege fight over PwC report
‘In all circumstances unconscionable’: ASIC wins case against forex broker
Limitations defences not relevant to new claims in Victoria class actions, court told
Please login to bookmarkClose

Novartis has launched an appeal following a ruling by IP Australia that a proposed patent for an oral form of its top-selling multiple sclerosis drug Gilenya is invalid for lack of inventive step.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au